This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Europe's premier partnering event
Save the date for next yearNovember 3–5, 2025 | Vienna, Austria

Steven Quay
Chairman of the Board and CEO at Atossa Therapeutics
Speaker

Profile

Steven Quay is a physician-scientist and founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for the prevention and treatment of breast cancer. He received his M.D., M.S., and Ph.D. from The University of Michigan, was a postdoctoral fellow at the Massachusetts Institute of Technology with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-Massachusetts General Hospital, a facility member of Harvard Medical School, and was on the faculty of Stanford University School of Medicine for a decade. His 390+ scientific contributions to medicine have been cited over 12,000 times, placing him in the top 1% of scientists worldwide. He is the author of two Amazon Best Seller books related to the COVID-19 Pandemic and has testified before the US Congress on medical research and healthcare national policy issues, as well as advised the US State Department on complex medical questions related to national security. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 91 US patents for inventions in 22 different fields of medicine. The medicines he has invented have been used by over 80 million people worldwide. His current passion is the prevention of the two million yearly breast cancer cases worldwide. A TEDx talk he delivered on breast cancer prevention has been viewed over 220,000 times. For more information, visit www.DrQuay.com or follow him on X (formerly Twitter) at @quay_dr.

Agenda Sessions

  • “Beautiful Life”: Atossa Therapeutics and the Karolinska Institute: The SMART study: A unique Swedish American collaboration to prevent breast cancer

    17:00